Subject(s)
Antibodies, Monoclonal/administration & dosage , Autoimmune Diseases/drug therapy , Dermatologic Agents/therapeutic use , Skin Diseases, Vesiculobullous/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Murine-Derived , Female , Humans , Male , Middle Aged , Rituximab , Treatment OutcomeABSTRACT
In North Jutland County, Denmark, we investigated whether use of oral glucocorticoids was associated with an increased risk of developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), and non-Hodgkin's lymphoma (NHL). From the Danish Cancer Registry we identified 5422 BCC, 935 SCC, 983 MM, and 481 NHL cases during 1989-2003. Using risk-set sampling we selected four age- and gender-matched population controls for each case from the Civil Registration System. Prescriptions for oral glucocorticoids before diagnosis were obtained from the Prescription Database of North Jutland County on the basis of National Health Service data. We used conditional logistic regression to estimate incidence rate ratios (IRRs), adjusting for chronic medical diseases (information about these were obtained from the National Patient Registry) and use of other immunosuppressants. We found slightly elevated risk estimates for BCC (IRR, 1.15 (95% CI: 1.07-1.25)), SCC (IRR, 1.14 (95% CI: 0.94-1.39)), MM (IRR, 1.15 (95% CI: 0.94-1.41), and NHL (IRR, 1.11 (95% CI: 0.85-1.46)) among users of oral glucocorticoids. Our study supports an overall association between glucocorticoid use and risk of BCC that cannot be explained by the presence of chronic diseases or concomitant use of other immunosuppressants.
Subject(s)
Glucocorticoids/adverse effects , Lymphoma, Non-Hodgkin/chemically induced , Skin Neoplasms/chemically induced , Administration, Oral , Aged , Carcinoma, Basal Cell/chemically induced , Carcinoma, Squamous Cell/chemically induced , Case-Control Studies , Female , Humans , Male , Melanoma/chemically induced , Middle Aged , Risk FactorsABSTRACT
Diuretics have photosensitising properties. However, little is known about how these diuretics affect the risk of skin cancers. In North Jutland County, Denmark, we investigated whether the use of photosensitising diuretics was associated with an increased risk for developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and malignant melanoma (MM). From the cancer registry, we identified primary cases of BCC, SCC and MM during the period of 1989-2003. We selected four population controls for each case from the Danish Civil Registration System, matched on age and gender. Prescriptions for photosensitising diuretics before cancer diagnosis were ascertained in the county's Prescription Database. We used conditional logistic regression to compute incidence rate ratio (IRR), controlling for the chronic medical conditions and for the previous use of oral glucocorticoids. We found an increased risk of SCC (IRR of 1.79 (95% confidence interval (CI): 1.45-2.21)) and MM (IRR of 1.43 (95% CI: 1.09-1.88)) among users of combined amiloride and hydrochlorothiazide therapy. An increased risk of MM (IRR of 3.30 (95% CI: 1.34-8.10)) was found among users of indapamide. We found little associations with risk of BCC. Our findings provide evidence that the use of some photosensitising diuretics is associated with an increased risk for SCC and MM.
Subject(s)
Dermatitis, Phototoxic/complications , Diuretics/adverse effects , Skin Neoplasms/etiology , Aged , Carcinoma, Squamous Cell/etiology , Case-Control Studies , Humans , Melanoma/etiology , Middle Aged , Risk FactorsABSTRACT
BACKGROUND: Nonmelanoma skin cancer (NMSC) is a growing public health problem among Caucasians, thus mortality data that may provide insight into the clinical course and foster our understanding of NMSC are important. OBJECTIVES: We examined total and cause-specific mortality among patients with NMSC registered in the Danish Cancer Registry from 1978 to 2001. METHODS: A total of 82 837 patients with basal cell carcinoma (BCC) and 13 453 patients with squamous cell carcinoma (SCC) were followed through the National Death Registry for specific causes of death. Standardized mortality ratios (SMRs) were computed based on mortality rates in the general population. RESULTS: Among patients with BCC, we found a slightly reduced total mortality [SMR 0.97, 95% confidence interval (CI) 0.96-0.98] with decreased SMRs seen for chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD) and diabetes mellitus. The SMR for suicide was increased. Among patients with SCC, we found an increased total mortality (SMR 1.30, 95% CI 1.26-1.33) due primarily to excess deaths from cancers, COPD, CVD and infectious diseases. CONCLUSIONS: We found markedly different mortality patterns among patients with BCC and those with SCC, suggesting important differences in the clinical course of these patients.
